Global Multiplex Assay Market Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,900	298 Pages	Inkwood Research	March, 2024	INKR18647244

Best Price Guarantee
Price	from $2,900
Length	298 Pages
Publisher	Inkwood Research
Published Date	March, 2024
SKU	INKR18647244

Global Multiplex Assay Market Forecast 2024-2032

KEY FINDINGS

The global multiplex assay market is set to record a CAGR of 8.12% over the forecast period, 2024-2032. The market growth is facilitated by key factors like increased government funding as well as research and development activities, the growing preference for multiplex assays over conventional assays, and the rising adoption of personalized medicines.

MARKET INSIGHTS

A multiplex assay is a procedure in which several analytes, including proteins, cytokines, biomolecules, growth factors, chemokines, and others, are profiled by detecting and quantifying them simultaneously. The assay is utilized to amplify multiple targets in a polymerase chain reaction (PCR) and gather added information from minute quantities of proteins or other analytes in less time compared to traditional methods like ELISA.

Multiplex assays hold tremendous potential in the research and development of drugs for the treatment of diseases such as cancer and cardiovascular diseases. For instance, bead-based Luminex xMAP multiplex assay offers a platform for cancer biomarker assays compatible with plasma, cultured cells, serum, as well as other biological samples. The American Association of Cancer Research (AACR) designed the multiplex immunoassay that assisted in the examination of acquired resistance to receptor tyrosine kinase (RTK) inhibitors. Moreover, RTK is utilized as a target for drug development to treat cancer.

REGIONAL INSIGHTS

The global multiplex assay market growth assessment includes the geographical analysis of North America, Europe, Asia-Pacific, and Rest of World. North America is set to harbor the highest market share by the end of the forecast period. The market growth is attributed to key drivers such as the increasing research and development activities of new drugs as well as treatment options, the rise in government funds for detecting new biomarkers, and the growing incidence of chronic conditions like stroke and cancer.

COMPETITIVE INSIGHTS

The intensity of competitive rivalry within the global multiplex assay market is anticipated to remain high over the projected years. Companies in the market adopt several strategies, including new product developments, mergers and acquisitions, and collaborations, in order to compete and retain their market share. Some of the leading firms operating in the market include F. Hoffmann-la Roche, Agilent Technologies Inc, Qiagen NV, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology: 1.1. Study Objectives; 1.2. Methodology; 1.3. Assumptions & Limitations
2. Executive Summary: 2.1. Market Size & Estimates; 2.2. Market Overview; 2.3. Scope Of Study; 2.4. Crisis Scenario Analysis; 2.4.1. Impact Of Covid-19 On Multiplex Assay Market; 2.5. Major Market Findings; 2.5.1. Software And Services Sector Emerges As The Rapidly Expanding Product & Service Segment; 2.5.2. Protein-based Multiplex Assay Is The Highest Revenue-generating Type; 2.5.3. Research & Development Applications Dominate Market Share; 2.5.4. Multiplex Pcr Technology Demonstrates Faster Growth; 2.5.5. Pharmaceutical And Biotechnology Companies Are Major Users Of Multiplex Assays
3. Market Dynamics: 3.1. Key Drivers; 3.1.1. Escalating Incidence Of Chronic Diseases; 3.1.2. Growing Preference For Multiplex Assays Over Conventional Approaches; 3.1.3. Increasing Acceptance Of Personalized Medicine; 3.2. Key Restraints; 3.2.1. Overcoming The Difficulty Of Establishing A Sufficient Assay Range; 3.2.2. Challenges Associated With Cross-reactivity And Assay Interference; 3.2.3. Shortage Of Skilled Professionals
4. Key Analytics: 4.1. Key Market Trends; 4.1.1. Rising Drug Discovery Endeavors; 4.1.2. Progress In Assay Platform Technology; 4.1.3. Rapid Expansion Of Companion Diagnostics; 4.2. Porter’s Five Forces Model; 4.2.1. Buyers Power; 4.2.2. Suppliers Power; 4.2.3. Substitution; 4.2.4. New Entrants; 4.2.5. Industry Rivalry; 4.3. Growth Prospect Mapping; 4.3.1. Growth Prospect Mapping For United States; 4.3.2. Growth Prospect Mapping For Germany; 4.3.3. Growth Prospect Mapping For India; 4.4. Market Maturity Analysis; 4.5. Market Concentration Analysis; 4.6. Key Buying Criteria; 4.6.1. Coverage Of Analytes; 4.6.2. Rapidity; 4.6.3. Ability To Multiplex; 4.6.4. User-friendliness; 4.6.5. Automation Potential; 4.7. Value Chain Analysis; 4.7.1. Research And Development (R&D); 4.7.2. Manufacturing And Production; 4.7.3. Distribution And Supply Chain; 4.7.4. Clinical Application And Data Analysis; 4.7.5. Market Research And Commercialization
5. Market By Product And Service: 5.1. Reagents And Consumables; 5.1.1. Market Forecast Figure; 5.1.2. Segment Analysis; 5.2. Instruments And Accessories; 5.2.1. Market Forecast Figure; 5.2.2. Segment Analysis; 5.3. Software And Services; 5.3.1. Market Forecast Figure; 5.3.2. Segment Analysis
6. Market By Type: 6.1. Protein-based Multiplex Assay; 6.1.1. Market Forecast Figure; 6.1.2. Segment Analysis; 6.2. Nucleic Acid-based Multiplex Assay; 6.2.1. Market Forecast Figure; 6.2.2. Segment Analysis; 6.3. Other Types; 6.3.1. Market Forecast Figure; 6.3.2. Segment Analysis
7. Market By Application: 7.1. Research And Development; 7.1.1. Market Forecast Figure; 7.1.2. Segment Analysis; 7.2. Clinical Diagnostics; 7.2.1. Market Forecast Figure; 7.2.2. Segment Analysis; 7.3. Companion Diagnostics; 7.3.1. Market Forecast Figure; 7.3.2. Segment Analysis
8. Market By Technology: 8.1. Multiplex Protein Microarray; 8.1.1. Market Forecast Figure; 8.1.2. Segment Analysis; 8.2. Multiplex Pcr; 8.2.1. Market Forecast Figure; 8.2.2. Segment Analysis; 8.3. Other Technologies; 8.3.1. Market Forecast Figure; 8.3.2. Segment Analysis
9. Market By End-user: 9.1. Pharmaceutical & Biotechnology Companies; 9.1.1. Market Forecast Figure; 9.1.2. Segment Analysis; 9.2. Research Institutes; 9.2.1. Market Forecast Figure; 9.2.2. Segment Analysis; 9.3. Clinical Laboratories; 9.3.1. Market Forecast Figure; 9.3.2. Segment Analysis; 9.4. Hospitals; 9.4.1. Market Forecast Figure; 9.4.2. Segment Analysis
10. Geographical Analysis: 10.1. North America; 10.1.1. Market Size & Estimates; 10.1.2. North America Multiplex Assay Market Drivers; 10.1.3. North America Multiplex Assay Market Challenges; 10.1.4. Key Players In North America Multiplex Assay Market; 10.1.5. Country Analysis; 10.1.5.1. United States; 10.1.5.1.1. United States Multiplex Assay Market Size & Opportunities; 10.1.5.2. Canada; 10.1.5.2.1. Canada Multiplex Assay Market Size & Opportunities; 10.2. Europe; 10.2.1. Market Size & Estimates; 10.2.2. Europe Multiplex Assay Market Drivers; 10.2.3. Europe Multiplex Assay Market Challenges; 10.2.4. Key Players In Europe Multiplex Assay Market; 10.2.5. Country Analysis; 10.2.5.1. Germany; 10.2.5.1.1. Germany Multiplex Assay Market Size & Opportunities; 10.2.5.2. United Kingdom; 10.2.5.2.1. United Kingdom Multiplex Assay Market Size & Opportunities; 10.2.5.3. France; 10.2.5.3.1. France Multiplex Assay Market Size & Opportunities; 10.2.5.4. Italy; 10.2.5.4.1. Italy Multiplex Assay Market Size & Opportunities; 10.2.5.5. Spain; 10.2.5.5.1. Spain Multiplex Assay Market Size & Opportunities; 10.2.5.6. Belgium; 10.2.5.6.1. Belgium Multiplex Assay Market Size & Opportunities; 10.2.5.7. Poland; 10.2.5.7.1. Poland Multiplex Assay Market Size & Opportunities; 10.2.5.8. Rest Of Europe; 10.2.5.8.1. Rest Of Europe Multiplex Assay Market Size & Opportunities; 10.3. Asia-pacific; 10.3.1. Market Size & Estimates; 10.3.2. Asia-pacific Multiplex Assay Market Drivers; 10.3.3. Asia-pacific Multiplex Assay Market Challenges; 10.3.4. Key Players In Asia-pacific Multiplex Assay Market; 10.3.5. Country Analysis; 10.3.5.1. China; 10.3.5.1.1. China Multiplex Assay Market Size & Opportunities; 10.3.5.2. Japan; 10.3.5.2.1. Japan Multiplex Assay Market Size & Opportunities; 10.3.5.3. India; 10.3.5.3.1. India Multiplex Assay Market Size & Opportunities; 10.3.5.4. Australia & New Zealand; 10.3.5.4.1. Australia & New Zealand Multiplex Assay Market Size & Opportunities; 10.3.5.5. South Korea; 10.3.5.5.1. South Korea Multiplex Assay Market Size & Opportunities; 10.3.5.6. Thailand; 10.3.5.6.1. Thailand Multiplex Assay Market Size & Opportunities; 10.3.5.7. Indonesia; 10.3.5.7.1. Indonesia Multiplex Assay Market Size & Opportunities; 10.3.5.8. Vietnam; 10.3.5.8.1. Vietnam Multiplex Assay Market Size & Opportunities; 10.3.5.9. Rest Of Asia-pacific; 10.3.5.9.1. Rest Of Asia-pacific Multiplex Assay Market Size & Opportunities; 10.4. Rest Of World; 10.4.1. Market Size & Estimates; 10.4.2. Rest Of World Multiplex Assay Market Drivers; 10.4.3. Rest Of World Multiplex Assay Market Challenges; 10.4.4. Key Players In Rest Of World Multiplex Assay Market; 10.4.5. Regional Analysis; 10.4.5.1. Latin America; 10.4.5.1.1. Latin America Multiplex Assay Market Size & Opportunities; 10.4.5.2. Middle East & Africa; 10.4.5.2.1. Middle East & Africa Multiplex Assay Market Size & Opportunities
11. Competitive Landscape: 11.1. Key Strategic Developments; 11.1.1. Mergers & Acquisitions; 11.1.2. Product Launches & Developments; 11.1.3. Partnerships & Agreements; 11.1.4. Business Expansions & Divestitures; 11.2. Company Profiles; 11.2.1. Abcam; 11.2.1.1. Company Overview; 11.2.1.2. Product Portfolio; 11.2.2. Agilent Technologies Inc; 11.2.2.1. Company Overview; 11.2.2.2. Product Portfolio; 11.2.2.3. Strengths & Challenges; 11.2.3. Becton, Dickinson And Company (Bd); 11.2.3.1. Company Overview; 11.2.3.2. Product Portfolio; 11.2.3.3. Strengths & Challenges; 11.2.4. Bio-rad Laboratories Inc; 11.2.4.1. Company Overview; 11.2.4.2. Product Portfolio; 11.2.4.3. Strengths & Challenges; 11.2.5. Bio-techne Corporation; 11.2.5.1. Company Overview; 11.2.5.2. Product Portfolio; 11.2.6. Cellcarta; 11.2.6.1. Company Overview; 11.2.6.2. Product Portfolio; 11.2.7. F. Hoffmann-la Roche Ltd; 11.2.7.1. Company Overview; 11.2.7.2. Product Portfolio; 11.2.7.3. Strengths & Challenges; 11.2.8. Illumina Inc; 11.2.8.1. Company Overview; 11.2.8.2. Product Portfolio; 11.2.8.3. Strengths & Challenges; 11.2.9. Merck Millipore; 11.2.9.1. Company Overview; 11.2.9.2. Product Portfolio; 11.2.10. Olink Proteomics Ab; 11.2.10.1. Company Overview; 11.2.10.2. Product Portfolio; 11.2.11. Qiagen Nv; 11.2.11.1. Company Overview; 11.2.11.2. Product Portfolio; 11.2.11.3. Strengths & Challenges; 11.2.12. Randox Laboratories Ltd; 11.2.12.1. Company Overview; 11.2.12.2. Product Portfolio; 11.2.13. Seegene Inc; 11.2.13.1. Company Overview; 11.2.13.2. Product Portfolio; 11.2.14. Siemens Healthineers Ag; 11.2.14.1. Company Overview; 11.2.14.2. Product Portfolio; 11.2.14.3. Strengths & Challenges; 11.2.15. Thermo Fisher Scientific Inc; 11.2.15.1. Company Overview; 11.2.15.2. Product Portfolio; 11.2.15.3. Strengths & Challenges